World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 13 December 2021
Main ID:  EUCTR2018-004392-12-FR
Date of registration: 13/05/2019
Prospective Registration: Yes
Primary sponsor: UCB Biopharma SPRL
Public title: A study to assess long-term safety, tolerability and efficacy of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy
Scientific title: An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Date of first enrolment: 10/09/2019
Target sample size: 34
Recruitment status: Not Recruiting
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004392-12
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product:
Placebo:
Other:
 
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries of recruitment
Belgium Canada Denmark France Germany Netherlands Spain United Kingdom
United States
Contacts
Name: Clin Trial Reg & Results Disclosure   
Address:  Alfred-Nobel-Strasse 10 40789 Monheim Germany
Telephone:
Email: clinicaltrials@ucb.com
Affiliation:  UCB BIOSCIENCES GmbH
Name: Clin Trial Reg & Results Disclosure   
Address:  Alfred-Nobel-Strasse 10 40789 Monheim Germany
Telephone:
Email: clinicaltrials@ucb.com
Affiliation:  UCB BIOSCIENCES GmbH
Key inclusion & exclusion criteria
Inclusion criteria:
- Subject who has completed one of the previous rozanolixizumab study(ies) that allow access to the present study (e.g. study CIDP01)
- Female subjects of childbearing potential must agree to use a highly effective method of birth control, during the study and for a period of 3 months after their final dose of investigational medicinal product (IMP)
- Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active during the study and for 3 months after the final administration of IMP
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 26
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 8

Exclusion criteria:
- Subject has any medical (acute or chronic illness) or psychiatric condition that, in the opinion of the investigator, could harm the subject or would compromise the subject’s ability to participate in this study
- Subject has a clinically relevant active infection (eg, sepsis, pneumonia, abscess)
- Subject has a known hypersensitivity to any components of rozanolixizumab
- Subject intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of rozanolixizumab
- Subject has an ongoing serious adverse event (SAE) or a medical condition in the parent study that the investigator considers to put the subject at a significantly increased risk of participating in CIDP04
- Subject has any planned elective surgery due to occur during the study dosing period which in the opinion of the investigator could interfere with study procedures


Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
MedDRA version: 20.0 Level: PT Classification code 10057645 Term: Chronic inflammatory demyelinating polyradiculoneuropathy System Organ Class: 10029205 - Nervous system disorders
Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Intervention(s)

Product Name: Rozanolixizumab
Product Code: UCB7665
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: ROZANOLIXIZUMAB
Current Sponsor code: UCB7665
Other descriptive name: Rozanolixizumab
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 140-

Primary Outcome(s)
Secondary Objective: Assess long-term clinical efficacy of doses of rozanolixizumab
Main Objective: Assess long-term safety and tolerability of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)
Timepoint(s) of evaluation of this end point: From Baseline until Follow-Up Visit (up to Week 32)
Primary end point(s): Occurrence of treatment-emergent adverse event (TAEs)
Secondary Outcome(s)
Secondary end point(s): No secondary end points are defined.
Timepoint(s) of evaluation of this end point: No secondary end points are defined.
Secondary ID(s)
2018-004392-12-GB
CIDP04
Source(s) of Monetary Support
UCB Biopharma SPRL
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date: 11/09/2019
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey